Literature DB >> 23702906

Differential effect of hypoxia on etoposide-induced DNA damage response and p53 regulation in different cell types.

Audrey Sermeus1, Magali Rebucci, Maude Fransolet, Lionel Flamant, Déborah Desmet, Edouard Delaive, Thierry Arnould, Carine Michiels.   

Abstract

Among the main causes of cancer cell resistance to chemotherapy are p53 mutation and hypoxic tumor microenvironment. However, the effect of hypoxia can be very different from one cell type to the other. We studied the effect of hypoxia on the etoposide-induced cell death in two cancer cell lines, HepG2 and A549 cells. Hypoxia decreased etoposide-induced apoptosis in HepG2 cells but not in A549 cells. Here, we evidenced two pathways, known to play important roles in cancer cell resistance, that are differently affected by hypoxia in these two cell types. First, in HepG2 cells, hypoxia decreased p53 protein level and activity by acting post-transcriptionally and independently of HIF-1. The results suggest an effect of hypoxia on p53 translation. On the other hand, in A549 cells, no effect of hypoxia was observed on p53 level. Secondly, hypoxia decreased DNA damage response in HepG2 cells while this was not the case in A549 cells. Indeed, a decrease in the phosphorylation level of CHK2 and H2AX with a decrease in ATM activity was observed. Importantly, these results evidenced that hypoxia can prevent cancer cell apoptosis by acting at different levels in the cell and that these effects are strongly cell-type dependent.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23702906     DOI: 10.1002/jcp.24409

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  9 in total

Review 1.  Understanding the Oxygen-Sensing Pathway and Its Therapeutic Implications in Diseases.

Authors:  Chengheng Liao; Qing Zhang
Journal:  Am J Pathol       Date:  2020-04-24       Impact factor: 4.307

2.  PHD3 Regulates p53 Protein Stability by Hydroxylating Proline 359.

Authors:  Javier Rodriguez; Ana Herrero; Shuijie Li; Nora Rauch; Andrea Quintanilla; Kieran Wynne; Aleksandar Krstic; Juan Carlos Acosta; Cormac Taylor; Susanne Schlisio; Alex von Kriegsheim
Journal:  Cell Rep       Date:  2018-07-31       Impact factor: 9.423

Review 3.  Tumor microenvironment-driven non-cell-autonomous resistance to antineoplastic treatment.

Authors:  Yidi Qu; Bo Dou; Horyue Tan; Yibin Feng; Ning Wang; Di Wang
Journal:  Mol Cancer       Date:  2019-03-30       Impact factor: 27.401

Review 4.  Protein Hydroxylation by Hypoxia-Inducible Factor (HIF) Hydroxylases: Unique or Ubiquitous?

Authors:  Moritz J Strowitzki; Eoin P Cummins; Cormac T Taylor
Journal:  Cells       Date:  2019-04-26       Impact factor: 6.600

Review 5.  The Role of Imaging Biomarkers to Guide Pharmacological Interventions Targeting Tumor Hypoxia.

Authors:  Bernard Gallez
Journal:  Front Pharmacol       Date:  2022-07-15       Impact factor: 5.988

6.  Liver p53 is stabilized upon starvation and required for amino acid catabolism and gluconeogenesis.

Authors:  Andreas Prokesch; Franziska A Graef; Tobias Madl; Jennifer Kahlhofer; Steffi Heidenreich; Anne Schumann; Elisabeth Moyschewitz; Petra Pristoynik; Astrid Blaschitz; Miriam Knauer; Matthias Muenzner; Juliane G Bogner-Strauss; Gottfried Dohr; Tim J Schulz; Michael Schupp
Journal:  FASEB J       Date:  2016-11-03       Impact factor: 5.834

7.  High-performance reoxygenation from PLGA-PEG/PFOB emulsions: a feedback relationship between ROS and HIF-1α.

Authors:  Jie Wang; Ruochen Wang; Niannian Li; Xi Shen; Gang Huang; Jun Zhu; Dannong He
Journal:  Int J Nanomedicine       Date:  2018-05-22

8.  Appropriate Sequence for Afatinib and Cisplatin Combination Improves Anticancer Activity in Head and Neck Squamous Cell Carcinoma.

Authors:  Eleonore Longton; Kathleen Schmit; Maude Fransolet; François Clement; Carine Michiels
Journal:  Front Oncol       Date:  2018-10-05       Impact factor: 6.244

9.  Taking Advantage of the Senescence-Promoting Effect of Olaparib after X-ray and Proton Irradiation Using the Senolytic Drug, ABT-263.

Authors:  Camille Huart; Maude Fransolet; Catherine Demazy; Benjamin Le Calvé; Stéphane Lucas; Carine Michiels; Anne-Catherine Wéra
Journal:  Cancers (Basel)       Date:  2022-03-12       Impact factor: 6.639

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.